TEVA - Teva outlines path to $2.5B AUSTEDO revenue in 2027 as innovative portfolio grows 33%
2025-11-05 13:02:58 ET
More on Teva Pharmaceutical
- Teva Pharmaceutical Industries Limited (TEVA) Q3 2025 Earnings Call Transcript
- Teva Pharmaceutical Industries Limited 2025 Q3 - Results - Earnings Call Presentation
- Teva Vs. Viatris: Who Will Dominate In President Trump's America?
- Teva gains after Q3 beat and guidance hike
- Teva Pharmaceutical Non-GAAP EPS of $0.78 beats by $0.11, revenue of $4.48B beats by $150M